Brief: Pharming Group Projects 2025 Revenues Of $376 Mln, Ahead Of Guidance
08/01/2026 06:11
Jan 8 (Reuters) - Pharming Group NV PHAR.AS: 2025 REVENUES ESTIMATED AT $376 MILLION, EXCEEDING GUIDANCE 2025 REVENUES REPRESENT 27% GROWTH VERSUS 2024 2025 OPERATING EXPENSES EXPECTED WITHIN $304-$308 MILLION RANGE TO SHARE 2026 FINANCIAL OUTLOOK AT UPCOMING INVESTOR DAY ON FEB 3 Source text: ID:nGNE158dvw Further company coverage: PHAR.AS (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 587 785 110;))